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e Estatística)). RESULTS: Our computed values vary across
countries and across time. The average STP rate for the 167
countries in the sample is 6.8% and the standard deviation 3.9%.
The ﬁgures ranged from -6.8% for Equatorial Guinea to 18.6%
for Armenia. For Brazil, STP rates display a decreasing proﬁle
across time, with an average rate of 4.7%. Computed ﬁgures
vary from 3.6% to 5.5%. CONCLUSIONS: The standardisation
of the use and estimation of discount rates in the economic
evaluation of health care programmes (EEHCP) is a core quest,
especially with the increase of EEHCP as a tool for decision
making. The variation of STR rate results indicate the need for
country-speciﬁc discount rate estimation.
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OBJECTIVES: This study aims to compare the impact of two
different sources of resource use, self-report versus routine
registrations, on incremental cost-effectiveness ratios (ICERs).
METHODS: Data were obtained from a cost-effectiveness study
performed alongside a two-year randomized controlled trial
evaluating the effect of an INTERdisciplinary COMmunity-
based management program (INTERCOM) for patients with
chronic obstructive pulmonary disease (COPD). The program
consisted of exercise training, nutritional therapy, education and
smoking cessation support offered by community-based physio-
therapists and dieticians and hospital-based respiratory nurses.
Data on caregiver visits, hospitalizations, diet nutrition, devices,
(un)paid help, travel expenses and time lost from paid work over
the two-year period were collected using a cost booklet. In addi-
tion, data on hospital admissions and outpatient visits, visits to
the physiotherapist, dietician or respiratory nurse, diet nutrition
and outpatient medication were obtained from hospital- and
billing records and local pharmacies. The cost per QALY was
calculated in two ways, using data from the cost booklet or
registrations. RESULTS: In total 175 patients were included in
the study. Agreement between self-report and registrations was
good for hospitalizations (r = 0.96), diet nutrition (r = 0.91) and
physiotherapist visits (r = 0.89), but above 0.58 for all other
types of care. The total cost difference between the registrations
and the cost booklet was €464 with the highest difference for
hospitalizations 386 euro. Based on the cost booklet the cost
difference between the treatment group and usual care was
€2,444 (95% CI: -819–5,950), which resulted in an ICER of
€29,100/QALY. For the registrations, the results were €2,498
(95% CI: -88–6,084) and €29,390/QALY, respectively. No dif-
ferences were found in the cost-effectiveness planes and the
acceptability curves between the two methods. CONCLUSIONS:
This study showed that the use of self-reported data or data from
routine registrations effected within group costs, but not between
group costs or the ICERs.
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OBJECTIVES: To assess trends in the prevalence and type of
economic analysis alongside randomized controlled trials (piggy-
back trials) published between 1997 and 2007. METHODS: We
searched Medline for a total number of Randomized Controlled
Trials published between 1997 and 2007. Economic studies
alongside RCTs were searched by using the additional MeSH
terms, costs and cost analysis. The abstract of each retrieved,
English-language study was reviewed and economic studies
alongside RCTs were identiﬁed. Included studies were catego-
rized further by the type of analysis, perspective and interven-
tions. RESULTS: Our search identiﬁed a total of 131,454 RCTs
and 2820 economic analysis alongside RCTs. A total of 2077
studies met inclusion criteria and further analyzed. Only 1.58%
of published RCTs included economic analysis. The prevalence
of economic studies alongside RCTs as a proportion of RCTs was
fairly constant over 1997–2007, except for the year 2000 where
a higher prevalence (2.07%) was observed. Cost effectiveness
analyses was most frequently reported (46.12%) followed by
cost minimization (2.74%), cost beneﬁt (2.6%) and cost utility
(1.4%). More than one type of analyses was reported in 3.17%
of studies. The remaining 44.05 % of studies were either cost
analysis or cost-consequence analysis or were unclear. The inter-
ventions considered in the trials were drugs (36.3%), devices or
surgical techniques (22.14%), behavioral studies (4.91%), pre-
ventive studies (3.9%), and others (30.38%).The perspective of
economic analysis was stated in only 8.32% of studies. Federal,
hospital, patient, payer, societal and state agency perspective
were reported by 1.2%, 1.3%, 0.38%, 1.05%, 2.84%, and
0.52% of studies respectively. CONCLUSIONS: We observed an
increase in the prevalence of economic analysis in randomized
controlled trials than earlier years. Also, the number of drug
trials and devices and surgical technique trials has increased from
before 1997. The reporting of trial perspective was found very
low. This could be because of external-validity problems with
piggy-back trials.”
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OBJECTIVES: Economic evaluation of health technologies is
increasingly used to inform decision-making in health policy. It is
standard practice in cost-effectiveness analysis to discount future
health beneﬁts at the same rate as costs and to apply a baseline
rate between three and ﬁve percent a year. Public health advo-
cates of prevention programmes often argue that devaluing
future health gains through discounting is inappropriate. The
purpose of this paper is to re-examine the arguments of the social
time preference approach for discounting health beneﬁts at some
positive rate and at the same rate as the costs. METHODS: The
paper is based on a systematic review of the literature on the
foundations of discounting in the economic evaluation of health
care programmes published during the time period 1989–2008.
RESULTS: According to the social time preference approach the
main arguments for discounting are the individual’s uncertainty
about the returns of investment, diminishing marginal utility and
pure time preference. None of these arguments convincingly
supports a positive and distinct discount rate for health gains.
Particularly the argument of pure time preference is challenged,
e.g. by the problem of myopia, the divergence between private
and collective decision behaviour, and the neglect of distribu-
tional concerns of public health policy. A more fundamental
weakness of the welfaristic framework is that is does not provide
an appropriate conceptual basis for dealing with the question
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